Identification and Molecular Cloning of Tactile. A Novel Human T Cell Activation Antigen That is a Member of the Ig Gene Superfamily
Overview
Authors
Affiliations
We have identified and cloned cDNA for a novel cell-surface protein that we have named Tactile for T cell activation, increased late expression. It is expressed on normal T cell lines and clones, and some transformed T cells, but no other cultured cell lines tested. It is expressed at low levels on peripheral T cells and is strongly up-regulated after activation, peaking 6 to 9 days after the activating stimulus. It is also up-regulated on NK cells activated in allogeneic cultures. It is not found on peripheral B cells but is expressed at very low levels on activated B cells. Tactile-specific mAb immunoprecipitates a band of 160 kDa when reduced and bands of 240, 180, and 160 kDa nonreduced. Using an antiserum produced with affinity-purified Tactile protein to screen a lambda gt11 library, we have identified Tactile cDNA. Northern blot analysis shows an expression pattern similar to that of the protein and transfection of COS cells with the full-length 5.2-kb cDNA results in cell-surface expression. Comparison with the sequence databanks show that Tactile is a member of the immunoglobulin gene superfamily, with similarity to Drosophila amalgam, the melanoma Ag MUC-18, members of the carcinoembryonic Ag family, the poliovirus receptor, and the neural cell adhesion molecule. The deduced primary sequence encodes a protein with three Ig domains, a long serine/threonine/proline-rich region typical of an extensively O-glycosylated domain, a transmembrane domain, and a 45 residue cytoplasmic domain. These data suggest that Tactile may be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response.
The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.
Murakami K, Ganguly S Front Immunol. 2024; 15:1441730.
PMID: 39156900 PMC: 11327090. DOI: 10.3389/fimmu.2024.1441730.
Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling.
Wu L, Park S, Jakobsson H, Shackleton M, Moller A Cancers (Basel). 2024; 16(11).
PMID: 38893071 PMC: 11171058. DOI: 10.3390/cancers16111950.
Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P, Liu X, Gu Z, Jiang Z, Zhao S, Song Y Biomark Res. 2024; 12(1):7.
PMID: 38229100 PMC: 10790541. DOI: 10.1186/s40364-023-00543-z.
CD96 as a Potential Immune Regulator in Cancers.
Feng S, Isayev O, Werner J, Bazhin A Int J Mol Sci. 2023; 24(2).
PMID: 36674817 PMC: 9866520. DOI: 10.3390/ijms24021303.
An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses.
Wang C, Choy F, Sanny A, Murakami T, Tan A, Lam K Cells. 2023; 12(2).
PMID: 36672244 PMC: 9856660. DOI: 10.3390/cells12020309.